Delee is a medical device company that has developed a groundbreaking screening test for cancer therapy management. Their innovative technology allows physicians to perform early diagnosis at a significantly lower cost. Delee's main focus is on the CytoCatch™ technology, a high-performance isolation platform for circulating tumor cells (CTCs).

This cutting-edge system captures and analyzes CTCs with the highest standards of efficiency and reproducibility in a fully automated manner. The CytoCatch™ isolation device boasts outstanding recovery rates above 97%, making it ideal for efficiently separating blood cancer cells. Moreover, being fully automated, it minimizes human errors and cell loss due to manual steps, further enhancing reliability and reproducibility.

Additionally, Delee offers the CytoCatch™ imaging system, which incorporates advanced computer vision and machine learning algorithms to accurately classify and enumerate CTCs isolated from a sample. This customizable system allows researchers to tailor their experiments to their specific needs. Delee's CytoCatch™ technology also enables molecular analyses to assess the genetic characteristics of captured cells, going beyond simple enumeration.

Researchers have the freedom to construct their own protocols and work with rare cells of different origins. With Delee's products and services, scientists and clinicians can push the boundaries of cancer research and therapy management, ultimately improving patient outcomes in the fight against this devastating disease